Summary
Global Bispecific Antibodies for Cancer Market 2023-2027
The analyst has been monitoring the bispecific antibodies for cancer market and is forecast to grow by $400.72 mn during 2022-2027, accelerating at a CAGR of 8.82% during the forecast period. Our report on the bispecific antibodies for cancer market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of cancer, advantages of bispecific antibodies over monoclonal antibodies, and strong pipeline.
The bispecific antibodies for cancer market is segmented as below:
By Type
• CD19 or CD3
• CD30 or CD16A
By Distribution Channel
• Hospitals
• Retail pharmacies
• Online
By Geography
• North America
• Europe
• Asia
• Rest of World (ROW)
This study identifies the emerging bispecific antibody generation platforms as one of the prime reasons driving the bispecific antibodies for cancer market growth during the next few years. Also, increase in strategic alliances. and strong R&D in China will lead to sizable demand in the market.
The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the bispecific antibodies for cancer market covers the following areas:
• Bispecific antibodies for cancer market sizing
• Bispecific antibodies for cancer market forecast
• Bispecific antibodies for cancer market industry analysis
This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading bispecific antibodies for cancer market vendors that include ABL Bio Inc., AFFIMED N.V., Akeso Inc., Amgen Inc., Aptevo Therapeutics Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Eli Lilly and Co., EPIMAB BIOTHERAPEUTICS INC., F STAR THERAPEUTICS INC., F. Hoffmann La Roche Ltd., Glenmark Pharmaceuticals Ltd., Johnson and Johnson, Mereo BioPharma Group Plc, Merus N.V., Pfizer Inc., Regeneron Pharmaceuticals Inc., TG Therapeutics Inc., Xencor Inc., and Y mAbs Therapeutics Inc. Also, the bispecific antibodies for cancer market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
